Recruiting
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT07782970· Phase 3· GlaxoSmithKline· Source
Contact: Kevin Choi (principal investigator)
Recruiting
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
NCT07602855· Phase 1/2· GlaxoSmithKline· Source
Contact: Ghassan Al-Jazayrly (principal investigator)
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Contact: William Towner (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672· Phase 2· GlaxoSmithKline· Source
Contact: Robert Vescio (principal investigator)
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395· Phase 2· GlaxoSmithKline· Source
Contact: Myanh Pardee (principal investigator)
Recruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455· Phase 1/2· GlaxoSmithKline· Source
Contact: Nicolaos Palaskas (principal investigator)
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Contact: Joseph Lamb (principal investigator)
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227· Phase 3· GlaxoSmithKline· Source
Contact: Joseph Lamb (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Ghassan Al-Jazayrly (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Heinz-Josef Lenz (principal investigator)
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397· Phase 2· ViiV Healthcare· Source
Active, not recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847· Phase 1/2· GlaxoSmithKline· Source
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606· Phase 3· GlaxoSmithKline· Source
Contact: Suzanne Kafaja (principal investigator)
Active, not recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· Phase 3· ViiV Healthcare· Source
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Norah Terrault (principal investigator)
Active, not recruiting
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249· Phase 4· GlaxoSmithKline· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Deborah Wong (principal investigator)
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· Phase 2/3· GlaxoSmithKline· Source
Contact: Elizabeth Volkmann (principal investigator)
Active, not recruiting
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471· Phase 2· ViiV Healthcare· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Gary Buchschacher Jr (principal investigator)
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839· Phase 1/2· GlaxoSmithKline· Source
Contact: Ghassan Al-Jazayrly (principal investigator)
Active, not recruiting
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562· Phase 2· GlaxoSmithKline· Source
Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247· Phase 2· GlaxoSmithKline· Source
Contact: Bobbie Rimel (principal investigator)
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· Phase 3· ViiV Healthcare· Source